CVS SEC Filing News — CVS Health Corporation

Latest SEC filings for CVS Health Corporation (CVS) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-08-17.

CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans; medical management capabilities; Medicare Advantage and Medicare Supplement plans; prescription drug plans (PDPs); and Medicaid health care management services. It serves employer groups, individuals, college students, part-time …
Sector: Healthcare Industry: Healthcare Plans Market Cap: $118.5B
20
Total Filings
0
Bullish Classifications
1
Bearish Classifications
14
Insider Transactions
3
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for CVS currently lean bearish. Of the 20 filing records displayed, 1 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
CVS Filing Activity Snapshot 2026-05-15 — 2026-08-17
Insider Transactions (Form 4)
0 buys vs 1 sell
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$317.47M
ROBBINS LARRY (Director) · 2026-05-21
3,372,000 shares · Form 4
Form 144 Notices
2
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 14 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 14 filings in this group are Form 4s for CVS Health Corporation.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 14 insider filings shown, the breakdown is 9 compensation award, 3 tax withholding, 1 disposition to issuer and 1 open-market sale. 1 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×9
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Tax withholding ×3
Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.
Disposition to issuer ×1
Shares were surrendered to or repurchased by the issuer rather than sold to other investors.
Open-market sale ×1
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Form 4 Tax withholding Tax / Compensation Filing 2026-06-29

CVS insider Form 4 filed for equity award, exercise, or tax withholding

Clark James David (SVP, Cont & Chief Acct Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 454 $90.98 $41.3K
Filing: Form 4 (Insider Transaction) Insider: Clark James David (SVP, Cont & Chief Acct Officer) Shares: 454
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-06-01

CVS insider Form 4 filed for equity award, exercise, or tax withholding

Newman Brian (EVP, Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 2,478 $90.98 $225.4K
Filing: Form 4 (Insider Transaction) Insider: Newman Brian (EVP, Chief Financial Officer) Shares: 2,478
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-06-01

CVS insider Form 4 filed for equity award, exercise, or tax withholding

Compton-Phillips Amy (EVP, Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 7,618 $90.98 $693.1K
Filing: Form 4 (Insider Transaction) Insider: Compton-Phillips Amy (EVP, Chief Medical Officer) Shares: 7,618
View on SEC EDGAR → Open Filing Document →
Form 4 Disposition to issuer Tax / Compensation Filing 2026-05-22

CVS insider Form 4 filed for equity award, exercise, or tax withholding

AGUIRRE FERNANDO (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were surrendered to or repurchased by the issuer rather than sold to other investors.

Transactions reported on this filing
Code Nature Shares Price Value
D Disposition to issuer 30,437 $93.78 $2.85M
D Disposition to issuer 1,563 $93.50 $146.1K
Filing: Form 4 (Insider Transaction) Insider: AGUIRRE FERNANDO (Director) Shares: 32,000
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-05-21

CVS insider ROBBINS LARRY (Director) sold 3,372,000 shares (~$317.47M)

ROBBINS LARRY, listed as Director at CVS HEALTH Corp, reported an open-market sale of 3,372,000 CVS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,983,387 $94.45 $187.33M
S Open-market sale 151 $95.18 $14.4K
S Open-market sale 797,628 $93.48 $74.56M
S Open-market sale 152,691 $94.81 $14.48M
S Open-market sale 66,881 $95.67 $6.40M
S Open-market sale 800 $96.28 $77.0K
S Open-market sale 370,462 $93.45 $34.62M
S Open-market sale derivative · Cash-Settled Swaps 378,000 $93.31 $35.27M
Filing: Form 4 (Insider Transaction) Insider: ROBBINS LARRY (Director) Shares: 3,372,000 Est. Value: $317.47M
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-15

CVS insider Form 4 filed for equity award, exercise, or tax withholding

Gallina John E (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Deferred Stock Units 1,447 $97.15 $140.6K
Filing: Form 4 (Insider Transaction) Insider: Gallina John E (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-15

CVS insider Form 4 filed for equity award, exercise, or tax withholding

Mahoney Michael F (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Deferred Stock Units 1,737 $97.15 $168.7K
Filing: Form 4 (Insider Transaction) Insider: Mahoney Michael F (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-15

CVS insider Form 4 filed for equity award, exercise, or tax withholding

AGUIRRE FERNANDO (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 1,563 $97.15 $151.8K
Filing: Form 4 (Insider Transaction) Insider: AGUIRRE FERNANDO (Director) Shares: 1,563
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-15

CVS insider Form 4 filed for equity award, exercise, or tax withholding

Balser Jeffrey R. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 2,058 $97.15 $199.9K
Filing: Form 4 (Insider Transaction) Insider: Balser Jeffrey R. (Director) Shares: 2,058
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-15

CVS insider Form 4 filed for equity award, exercise, or tax withholding

KIRBY J SCOTT (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 1,447 $97.15 $140.6K
Filing: Form 4 (Insider Transaction) Insider: KIRBY J SCOTT (Director) Shares: 1,447
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-15

CVS insider Form 4 filed for equity award, exercise, or tax withholding

Norwalk Leslie V (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 1,447 $97.15 $140.6K
Filing: Form 4 (Insider Transaction) Insider: Norwalk Leslie V (Director) Shares: 1,447
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-15

CVS insider Form 4 filed for equity award, exercise, or tax withholding

SANSONE GUY P (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 1,447 $97.15 $140.6K
Filing: Form 4 (Insider Transaction) Insider: SANSONE GUY P (Director) Shares: 1,447
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-15

CVS insider Form 4 filed for equity award, exercise, or tax withholding

DECOUDREAUX ALECIA A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Deferred Stock Units 1,447 $97.15 $140.6K
Filing: Form 4 (Insider Transaction) Insider: DECOUDREAUX ALECIA A (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-15

CVS insider Form 4 filed for equity award, exercise, or tax withholding

Finucane Anne A. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Deferred Stock Units 1,544 $97.15 $150.0K
Filing: Form 4 (Insider Transaction) Insider: Finucane Anne A. (Director)
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 2 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. CVS Health Corporation has 2 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-05-22

CVS Form 144 filed for proposed insider sale by AGUIRRE FERNANDO (32,000 shares) ~$3.03M

AGUIRRE FERNANDO filed a Form 144 with the SEC indicating intent to sell CVS (CVS HEALTH Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: AGUIRRE FERNANDO Shares: 32,000 Est. Value: $3.03M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-05-21

CVS Form 144 filed for proposed insider sale by FARAH ROGER N (2,817 shares) ~$263.9K

FARAH ROGER N filed a Form 144 with the SEC indicating intent to sell CVS (CVS HEALTH Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: FARAH ROGER N Shares: 2,817 Est. Value: $263.9K
View on SEC EDGAR → Open Filing Document →
Material Events 3 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 3 in this period for CVS Health Corporation. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-17

CVS filed 8-K — material company event

CVS HEALTH Corp filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-05

CVS filed 8-K — material company event

CVS HEALTH Corp filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-05-18

CVS filed 8-K — material company event

CVS HEALTH Corp filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for CVS Health Corporation.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-05

CVS filed Quarterly Report (10-Q)

CVS HEALTH Corp filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify CVS Health Corporation's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on CVS. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — CVS SEC Filings

More Tools for CVS

CVS Full Stock Analysis CVS Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper CVS analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the CVS stock analysis page.

CVS Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer